YOLFTbeta
Medpace Holdings Inc

Medpace Holdings Inc

MEDP · NASDAQ · Healthcare / Diagnostics & Research

653.94USD-2.90 (-0.44%)

Price History

Full chart

Market Stats

Previous Close656.84
Open660.25
Day Range644.77 – 660.25
52-Week Range373.00 – 677.90
Volume105.45K
Market Cap17.27B
P/E (TTM)36.36
Forward P/E31.95
EPS17.02
Dividend Yield0.00%
Beta1.15
50-Day Avg591.95
200-Day Avg522.11

About

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. August James Troendle M.D.
  • Employees6.50K
  • Headquarters5375 Medpace Way, Cincinnati, OH, United States, 45227, USA
  • Websitehttps://www.medpace.com

Leadership

  • Dr. August James Troendle M.D.CEO, President & Chairman · b. 1956
  • Mr. Kevin M. BradyCFO & Treasurer · b. 1975
  • Mr. Stephen P. Ewald J.D.Chief Compliance Officer, General Counsel & Corporate Secretary · b. 1969
  • Mr. Brad W. HansmanExecutive Vice President of Operations · b. 1983
  • Ms. Lauren MorrisAssociate Director of Investors Relations
  • Mr. Todd MeyersVice President of Business Development & Marketing
  • Mr. Weimin Gai MSSenior Vice President of Biometrics
  • Mr. John T. Wynne MBAChief Business Officer
  • Ms. Reinilde Heyrman M.D.Chief Medical Officer of Medical Department · b. 1961
  • Ms. Gina Leisring M.P.H.Senior Vice President of Clinical Monitoring

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue272.89M290.04M359.06M421.58M436.15M704.59M860.97M925.92M1.14B1.46B1.89B2.11B2.53B
Growth (%)-+6.28%+23.80%+17.41%+3.46%+61.55%+22.19%+7.54%+23.38%+27.80%+29.17%+11.84%+19.97%
Cost of Revenue148.40M156.31M202.66M249.47M261.46M489.06M615.27M647.20M814.22M1.03B1.36B1.45B1.77B
Gross Profit124.49M133.73M156.39M172.11M174.69M215.53M245.70M278.73M328.15M432.44M524.50M656.30M760.62M
Gross Margin45.62%46.11%43.56%40.83%40.05%30.59%28.54%30.10%28.73%29.62%27.81%31.12%30.06%
Operating Expense65.63M107.73M135.83M119.62M109.83M114.48M118.43M111.68M129.54M153.74M187.68M209.44M225.68M
Operating Income58.86M26.00M20.56M52.49M64.86M101.05M127.26M167.04M198.62M278.70M336.82M446.87M534.93M
Operating Margin21.57%8.96%5.73%12.45%14.87%14.34%14.78%18.04%17.39%19.09%17.86%21.19%21.14%
EBITDA87.66M94.06M88.95M99.45M110.98M139.85M150.45M186.57M223.08M308.11M362.50M505.17M570.50M
EBITDA Margin32.12%32.43%24.77%23.59%25.44%19.85%17.47%20.15%19.53%21.10%19.22%23.95%22.55%
Net Income24.84M-15.57M-8.67M13.43M39.12M73.19M100.44M145.38M181.85M245.37M282.81M404.39M451.12M
Net Income Margin9.10%-5.37%-2.42%3.18%8.97%10.39%11.67%15.70%15.92%16.81%15.00%19.17%17.83%
R&D---00--------
R&D as % of Total Revenue---0.00%0.00%--------
Interest Expense18.00M26.46M27.26M19.38M7.56M8.16M1.57M307.00K105.00K2.90M488.00K25.00M-
Interest Expense % of Total Revenue6.60%9.12%7.59%4.60%1.73%1.16%0.18%0.03%0.01%0.20%0.03%1.19%-

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-1.10B984.04M979.11M950.72M967.93M1.14B1.39B1.66B1.35B1.66B2.10B1.98B
Total Liabilities-694.94M570.57M368.39M447.19M378.23M416.79M584.90M707.01M966.11M1.10B1.28B1.52B
Total Equity-401.97M413.47M610.71M503.53M589.70M726.28M805.78M952.93M386.39M558.95M825.54M459.07M
Cash-54.28M14.88M37.10M26.48M23.27M131.92M277.77M461.30M28.27M245.45M669.44M497.05M
Total Debt-491.52M428.27M192.17M248.21M191.70M45.21M115.14M130.97M188.87M142.12M149.52M250.50M
Net Debt-437.23M363.00M126.54M195.13M56.45M-86.71M-162.62M-330.34M160.60M-103.33M-519.91M-246.55M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow98.14M75.20M85.87M91.73M97.39M156.58M201.87M258.68M263.33M388.05M433.37M608.82M713.22M
Investing Cash Flow-4.47M-908.47M-6.43M-13.42M-12.24M-16.97M-19.14M-31.21M-31.36M-38.74M-34.63M-28.31M-31.14M
Financing Cash Flow-95.85M882.20M-116.49M-58.01M-97.83M-141.58M-73.92M-82.28M-44.45M-775.77M-182.64M-154.01M-860.39M
Capital Expenditure4.56M5.32M6.46M13.54M12.29M16.02M17.91M31.34M28.27M36.88M36.65M36.55M31.36M
Free Cash Flow93.58M69.89M79.41M78.19M85.09M140.56M183.96M227.34M235.06M351.17M396.73M572.27M681.87M
Dividends Paid---00----22.07M11.38M--
FCF to OCF95.35%92.93%92.47%85.24%87.38%89.77%91.13%87.88%89.26%90.50%91.54%94.00%95.60%
Dividend Paid to FCF---0.00%0.00%----6.29%2.87%--

Earnings

Report DateAug 16, 2016Nov 3, 2016Feb 27, 2017May 1, 2017Jul 31, 2017Oct 30, 2017Feb 26, 2018Apr 30, 2018Jul 30, 2018Oct 29, 2018Feb 25, 2019Apr 29, 2019Jul 29, 2019Oct 28, 2019Feb 24, 2020Apr 28, 2020Jul 27, 2020Oct 26, 2020Feb 15, 2021Apr 26, 2021Jul 26, 2021Oct 25, 2021Feb 14, 2022Apr 25, 2022Jul 25, 2022Oct 24, 2022Feb 13, 2023Apr 24, 2023Jul 24, 2023Oct 23, 2023Feb 12, 2024Apr 22, 2024Jul 22, 2024Oct 21, 2024Feb 10, 2025Apr 21, 2025Jul 21, 2025Oct 22, 2025Feb 9, 2026Apr 22, 2026Jul 22, 2026Oct 21, 2026
EPS Estimate0.340.340.340.370.300.360.380.440.430.630.670.610.640.710.750.750.441.161.241.071.031.121.251.311.391.541.791.882.002.192.222.492.632.873.123.073.003.574.183.964.084.45
EPS Actual0.450.400.350.340.380.400.390.550.610.670.760.640.810.710.850.800.681.141.351.181.091.321.321.711.482.072.122.281.952.242.463.222.763.013.683.673.103.864.674.284.25-
Surprise32.35%17.65%2.94%-8.11%26.67%11.11%2.63%25.00%41.86%6.35%13.43%4.92%26.56%0.00%13.33%6.67%54.55%-1.72%8.87%10.28%5.83%17.86%5.60%30.53%6.47%34.42%18.44%21.28%-2.50%2.28%10.81%29.32%4.94%4.88%18.12%19.54%3.33%8.12%11.72%8.08%4.17%-
TimingPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap17.27B
Enterprise Value16.84B
Trailing P/E36.36
Forward P/E31.95
PEG Ratio2.93
Price / Sales6.21
Price / Book39.70
EPS17.02
Book Value15.55
Revenue (TTM)2.78B
Gross Profit (TTM)2.01B
EBITDA611.20M
Profit Margin17.67%
Operating Margin20.76%
Return on Equity162.15%
Return on Assets20.10%
Shares Outstanding27.91M
Shares Float22.56M
Beta1.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Hold
Based on 12 analystsTarget 581.83
  • Strong Buy
    2
  • Hold
    10

Ownership Breakdown

Institutions
91.24%
Insiders
19.46%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    2.47M8.85%
  • AQR Capital Management LLC
    1.35M4.85%
  • Vanguard Portfolio Management, LLC
    1.12M4.02%
  • Vanguard Capital Management, LLC
    1.01M3.62%
  • Geode Capital Management, LLC
    745.11K2.67%
  • State Street Corp
    682.23K2.44%
  • Wasatch Advisors LP
    636.60K2.28%
  • Amvescap Plc.
    577.57K2.07%
  • Renaissance Technologies Corp
    504.67K1.81%
  • Baillie Gifford & Co Limited.
    473.21K1.70%
  • Dimensional Fund Advisors, Inc.
    397.50K1.42%
  • Arrowstreet Capital Limited Partnership
    395.77K1.42%
  • UBS Group AG
    340.43K1.22%
  • T. Rowe Price Associates, Inc.
    289.51K1.04%

Top Fund Holders

  • iShares Core S&P Mid-Cap ETF
    790.32K2.83%
  • Vanguard MStar Total Stk Mkt Idx Invest
    726.38K2.60%
  • Vanguard Small Cap Index
    525.67K1.88%
  • Vanguard MStar Small Cap Growth Indx Inv
    301.73K1.08%
  • Invesco S&P MidCap Quality ETF
    296.07K1.06%
  • Vanguard Explorer Inv
    295.22K1.06%